Our website uses cookies. We use cookies to remember settings and to help provide you with the best experience we can. We also use cookies to continuously improve our website by compiling visitor statistics. Read more about cookies

Prof. dr. H.J. (Josef) Vormoor

Pediatric oncologist
Prof. dr. H.J. (Josef) Vormoor

Cancer is still one of the most important causes of death among children and our treatments are associated with considerable side effects and chronic health problems. My work activities focus on developing new and better treatments for children with leukemia.

Specialisme / subspecialisme: kindergeneeskunde/kinderoncologie

Kennis en ervaring
  • 1999 – 2005 Kinderoncoloog, Universitair Medisch Centrum Münster, Duitsland
  • 2006 – 2018 Kinderoncoloog, Great North Children’s Hospital, Groot-Britannië
  • 2007 – 2018 Sir James Spence Professor of Child Health, Universiteit Newcastle
  • 2013 – 2017 Directeur, Northern Institute for Cancer Research, Universiteit Newcastle
  • 2018 – 2023 Visiting Professor, Universiteit Newcastle
  • Vanaf 1 juni 2018 Hoofd Afdeling Hemato-oncologie, Prinses Maxima Centrum, Utrecht


  • 1990, Doktor der Medizin (Research MD), “The prognostic significance of Auer rods in childhood AML".


  • 1989-1990: ANIOS (“Arzt im Praktikum”), Kinderziekenhuis, Universitair Medisch Centrum Münster, Duitsland
  • 1991: Militaire dienstplicht als officier geneeskundige dienst, Duitse Marine
  • 1992-1994: Postdoctoraal onderzoeker, Hospital for Sick Children Toronto, Canada
  • 1995-1999: AIOS in kindergeneeskunde, Kinderziekenhuis, Universitair Medisch Centrum Münster, Duitsland (inclusief 3 maanden stamcel transplantatie aan het Fred Hutchinson Cancer Center in Seattle, VS)

Wetenschappelijke publicaties
  • 2018, RUNX1/ETO directly targets Cyclin D2 compelling cell cycle progression and leukemic propagation, doi: 
  • 2018, Epidemiology and Biology of Relapse after Stem Cell Transplantation, doi: 10.1038/s41409-018-0171-z. 
  • 2018, Accelerating drug development in pediatric cancer: a novel Phase I study design of venetoclax in relapsed/refractory malignancies. doi: 10.2217/fon-2018-0121. 
  • 2018, Allogeneic hematopoietic cell transplantation in Farber disease, doi: 10.1007/s10545-018-0171-6. 
  • 2017, The MLL recombinome of acute leukemias in 2017. doi: 10.1038/leu.2017.213.  2017, From Class Waivers to Precision Medicine in Paediatric Oncology, doi: 10.1016/S1470-2045(17)30442-4. 
  • 2017, Early phase clinical trials of anticancer agents in children and adolescents: an Innovative Therapies for Children with Cancer (ITCC) position paper, doi: 10.1038/nrclinonc.2017.59. 
  • 2017, Abundant and equipotent founder cells establish and maintain acute lymphoblastic leukaemia, doi: 10.1038/leu.2017.140. 
  • 2017, A population pharmacokinetic model of AT9283 in adults and children to predict the maximum tolerated dose in children with leukaemia, doi: 10.1111/bcp.13260.
Mijn publicaties in pubmed zijn te zien via deze link.

Telefoon 06-50006756 (secretariaat)